drugset / Trial / NCT01657981

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

NCT01657981

Phase 1 Completed 6 enrolled Astellas Pharma Europe B.V.
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The study aims to observe how YM150 was absorbed, distributed and excreted after dosing with a radio labeled drinking solution.

Timeline

Start
2007-02
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject darexaban Small molecule Oral

Indications

No indication recorded.